Unfortunately, we don't support Internet Explorer anymore as it has been replaced by Microsoft Edge. Please try using Edge or an alternative modern browser for the best experience.
As Interim CEO, Krish Ramanathan leads Gates MRI’s research and development of novel products and interventions for diseases disproportionately impacting the world’s most vulnerable populations. Previously, he served as Chief of Staff and Head of Strategic Development leading the development programs for the Gates MRI’s drug and vaccine candidates.
Krish brings 25 years of integrated pharmaceutical and biotechnology experience to his role, including leadership in development programs across vaccines and therapeutics. Prior to joining the Gates MRI, Krish served as Senior Vice President and Head of Immunology Portfolio & Assets at Johnson & Johnson Innovative Medicines R&D, where he led teams overseeing early- and late-stage development. Before joining J&J, Krish served at Novartis for 15 years where he held leadership roles spanning multiple therapeutic areas, leading teams to successful regulatory approvals.
Krish holds a Ph.D. in Biomedical Engineering from Johns Hopkins University. He has a M.S.E. in Biomedical Engineering from John Hopkins University and an undergraduate degree in Mechanical Engineering from the Indian Institute of Technology, Chennai.
